By Stephanie Holliday
CANNATREK has achieved Good Manufacturing Practice (GMP) accreditation from Australia’s Therapeutic Goods Administration (TGA) for its newly developed $5M processing facility in Shepparton.
This accreditation marks a significant milestone for Cannatrek, as it transitions from being primarily an agricultural company to becoming a complete pharmaceutical supply chain for medicinal cannabis treatments.
The $5M manufacturing facility is part of a broader planned $17M investment by Cannatrek into the Shepparton region that includes both cultivation and end-to-end manufacturing of medicinal cannabis products.
The organisation is not only investing in its processing facility but also its cannabis farm in our region, which is expected to begin cultivating cannabis plants in the coming year. This farm will supply the Shepparton processing facility, completing the supply chain from cultivation to distribution of finished medicines.
CFO and executive director of Cannatrek, Brett Schwarz, spoke of how when it came to selecting a region for a cannabis farm and production facility, Shepparton was the clear frontrunner.
“Here we are in Shepparton, an epicentre of farming activity, knowledge and an ideal climate for agricultural prosperity. We looked at other regions, but Shepparton ticked all the boxes,” said Mr Schwarz.
“Shepparton has the longest daylight hours outside of Darwin, it’s an ideal location establishing an end-to-end supply chain. This site will generate jobs for the region and we have put a lot of focus into developing this site.”
Brett Schwarz, alongside Head of Capital Projects and Cultivation Operations at Cannatrek Shaya Rubinstein, CEO and Cannatrek founder Tommy Huppert and Kim O’Keeffe, the Nationals Member for Shepparton District, welcomed the media for a tour of the facility last Tuesday.
